Aura Biosciences (AURA) Set to Announce Quarterly Earnings on Thursday

Aura Biosciences (NASDAQ:AURA) is expected to release its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of ($0.3681) per share for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, November 11, 2026 at 9:30 AM ET.

Aura Biosciences (NASDAQ:AURA) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.10). On average, analysts expect Aura Biosciences to post ($1.61) EPS for the current fiscal year and ($1.39) EPS for the next fiscal year.

Aura Biosciences Stock Up 1.6%

AURA opened at $6.40 on Thursday. Aura Biosciences has a 12 month low of $4.73 and a 12 month high of $9.53. The company has a fifty day simple moving average of $6.74 and a 200 day simple moving average of $6.68. The stock has a market cap of $663.71 million, a P/E ratio of -3.66 and a beta of 0.41.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on AURA. Wall Street Zen lowered Aura Biosciences from a “hold” rating to a “sell” rating in a report on Sunday, August 16th. HC Wainwright lowered their price target on Aura Biosciences from $24.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, August 11th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Aura Biosciences in a report on Monday, October 12th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $17.50.

Aura Biosciences Company Profile

Aura Biosciences, Inc (NASDAQ:AURA) is a clinical-stage biotechnology company developing targeted therapies for cancer. The company’s platform is designed to use tumor-targeting virus-like particles to selectively bind to cancer cells and deliver therapeutic payloads, with the goal of treating tumors while limiting damage to surrounding healthy tissue.

Aura’s lead product candidate is AU-011, also known as belzupacap sarotalocan, an investigational therapy being developed for primary choroidal melanoma, a form of eye cancer.